Alzheimer's disease (AD) is the most common cause of dementia and, as a consequence of increased lifespan and consequent population aging, is becoming increasingly prevalent. It is a chronic, progressive, and hitherto incurable neurodegenerative condition. Dysfunction of the beta-amyloid protein (Aβ) and microtubule-associated protein tau, resulting in neuronal degeneration, is associated with the main neuropathological features of Alzheimer's disease. The medications work to relieve symptoms but do not have disease-modifying effects and are still considered to be one of science's biggest challenges. This study indicates that research into AD is on the rise around the world because new forms of drugs are being pursued by the pharmaceutical industry and research institutions to treat and even cure Alzheimer's patients. We map out the possible future therapies for this disease by reviewing patent records, indicating the leading nations and pharmaceutical companies that have invested most in an attempt to drive progress towards findings about the disease and the production of new medicines.
Author (s) Details
Karinne Marieta Carvalho
School of Chemical – Federal University of Rio de Janeiro, Graduate Course on Technology of Biochemical and Chemical Processes, Av. Horácio Macedo, 2030, Technology Center, CEP: 21941-909, Brazil.
Eduardo Winter
INPI – Brazilian National Institute of Industrial Property, Praça Mauá, 7 – Centro, Rio de Janeiro, RJ – CEP 20081-240, Brazil.
Adelaide Maria de Souza Antunes
School of Chemical – Federal University of Rio de Janeiro, Graduate Course on Technology of Biochemical and Chemical Processes, Av. Horácio Macedo, 2030, Technology Center, CEP: 21941-909, Brazil and INPI – Brazilian National Institute of Industrial Property, Praça Mauá, 7 – Centro, Rio de Janeiro, RJ – CEP 20081-240, Brazil.
View Book :- https://stm.bookpi.org/NICST-V5/issue/view/22
No comments:
Post a Comment